Abstract
Northern European countries and countries bordering the Baltic Sea have witnessed an increase of vibriosis cases during recent heatwaves. Here, we described the epidemiology of vibriosis cases and the genetic diversity of Vibrio isolates from Norway, Sweden, Denmark, Finland, Poland, Estonia, and Latvia in 2018, a year with an exceptionally warm summer. We conducted a retrospective study and analysed demographics, geographic distribution, seasonality, causative species, and severity of non-travel related vibriosis cases in 2018. Data sources included surveillance systems, national laboratory notification databases and/or nationwide surveys to public health microbiology laboratories. Moreover, we performed whole genome sequencing and multilocus sequence typing of available isolates from 2014-2018 to map their genetic diversity.
In 2018, we identified 445 non-travel related vibriosis cases in the study countries, which was considerably higher than the median of 126 cases between 2014-2017 (range: 87-272). The main reported mode of transmission was exposure to seawater. We observed a species-specific geographic disparity of vibriosis cases across the Nordic-Baltic region. Developing severe vibriosis was associated with infections of Vibrio vulnificus (adjOR: 17.2; 95% CI: 3.3-90.5) or Vibrio parahaemolyticus (adjOR: 2.1; 95% CI: 1.0-4.5), being ≥65 years of age (65-79 years, adjOR: 3.9; 95% CI: 1.7-8.7; 80+ years, adjOR: 15.5; 95% CI: 4.4-54.3) or acquiring infections during summer (adjOR: 5.1; 95% CI: 2.4-10.9). Although phylogenetic analysis revealed diversity between Vibrio isolates, two V. vulnificus clusters (<10 SNPs) were identified. A share sentinel surveillance system for vibriosis during summer months might be highly valuable to monitor this emerging public health issue.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The project has been financially supported by the European Programme for Public Health Microbiology Training (EUPHEM), ECDC. The funder had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Ethical approval for this study was granted by Regional Committees for Medical Research Ethics - South East Norway, reference 2019/123/REK. The need for informed consent was waived by the ethics committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Last sentence of the abstract available in the medRxiv search page is now harmonised with the abstract text in the archived PDF manuscript.
Data Availability
The dataset analysed in the study contains individual-level data from various central health registries or laboratory databases from participating countries. Only fully anonymised data (i.e. data that are neither directly nor potentially indirectly identifiable) are permitted to be shared publicly. Therefore, legal restrictions prevent the researchers from publicly sharing the dataset used in the study. However, external researchers are freely able to request access to linked data to each national public health institute as per normal procedure for conducting health research in respective countries in line with national and European regulations concerning data protection. Sequencing data of isolates are public available through the European Nucleotide Archive (ENA).
